Pharmacokinetics of BID versus QID Dosing of Sulfadiazine in HIV-infected Patient

本研究是一项开放、随机、交叉的研究 磺胺嘧啶在人体内的药代动力学比较研究 每天两次或每天四次。十个人类 免疫缺陷病毒感染患者的CD4细胞计数低于 将招收500名学生。患者不能同时患有 机会性感染，必须愿意遵守 研究养生方法。这项研究旨在比较药代动力学 两种剂量的磺胺嘧啶的参数和血药浓度： QID 1000 mg，BID 2000 mg。此外，这项研究将评估 这些给药方案的安全性和耐受性。目前， 该研究已经获得了IRB的批准，并将在 接下来的1到2个月。

This study is an open-label, randomized, cross-over study to compare the pharmacokinetics of sulfadiazine given on a twice daily or four times daily schedule. Ten human immunodeficiency virus-infected patients with CD4 counts below 500 will be enrolled. Patients must not have concurrent opportunistic infections and must be willing to comply with the study regimen. The study is designed to compare pharmacokinetic parameters and serum concentrations of sulfadiazine at two doses: 1000mg QID and 2000mg BID. Additionally, this study will assess the safety and tolerability of these dosage regimens. Currently, the study has received IRB approval and will begin enrolling within the next 1 to 2 months.